Endonovo Therapeutics

Endonovo Therapeutics is a Los Angeles-based neurotechnology company focused on the development of wearable pulsed electromagnetic field (PEMF) devices designed to address neuroinflammation through non-invasive neuromodulation. The company's core technology delivers targeted electromagnetic energy to modulate biological processes associated with inflammation and neural dysfunction, offering a drug-free therapeutic alternative for patients. Their wearable form factor is central to their product strategy, enabling continuous, at-home use that distinguishes their approach from clinic-bound or surgical neuromodulation solutions. Endonovo's platform is primarily aimed at two high-burden indications: traumatic brain injury recovery and chronic pain management.

As a publicly traded company, Endonovo Therapeutics operates within the growing landscape of bioelectronic medicine and non-invasive neuromodulation, competing alongside both established medical device companies and emerging neurotechnology startups. The company has pursued clinical and regulatory development pathways to validate the safety and efficacy of its PEMF technology across its target indications. Their public status provides a degree of market transparency and access to capital markets to support ongoing research and product development efforts. Endonovo's clinical progress in addressing TBI, a condition with significant unmet medical need and limited approved therapeutic options, has been a focal point of its development narrative.

Endonovo Therapeutics represents a meaningful contributor to the broader neurotech industry's shift toward accessible, non-invasive intervention modalities that reduce reliance on pharmaceuticals and surgical procedures. Their work on neuroinflammation as a therapeutic target aligns with emerging scientific consensus around inflammation's central role in a range of neurological and pain conditions. By combining bioelectronic medicine principles with wearable consumer-friendly hardware, Endonovo is helping to expand the addressable patient population for neuromodulation therapies beyond those who qualify for implantable or in-clinic devices. Their focus on TBI recovery also places them at the intersection of neurotechnology and a growing national conversation around brain health, veterans' care, and sports-related head injuries.